Ceera Investments LLC Sells 6,654 Shares of Pfizer Inc. (NYSE:PFE)

Ceera Investments LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 12.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,397 shares of the biopharmaceutical company’s stock after selling 6,654 shares during the quarter. Ceera Investments LLC’s holdings in Pfizer were worth $1,204,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Swedbank AB lifted its holdings in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the period. Beckerman Institutional LLC bought a new position in shares of Pfizer during the third quarter valued at $376,000. Equitable Trust Co. lifted its holdings in shares of Pfizer by 4.6% during the third quarter. Equitable Trust Co. now owns 50,745 shares of the biopharmaceutical company’s stock valued at $1,469,000 after acquiring an additional 2,242 shares during the period. CWA Asset Management Group LLC bought a new position in shares of Pfizer in the third quarter valued at about $1,382,000. Finally, Holistic Planning LLC raised its holdings in shares of Pfizer by 215.8% in the third quarter. Holistic Planning LLC now owns 46,364 shares of the biopharmaceutical company’s stock valued at $1,342,000 after buying an additional 31,681 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Pfizer Price Performance

Pfizer stock opened at $26.71 on Friday. The firm has a market capitalization of $151.35 billion, a P/E ratio of 18.94, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The business has a 50-day moving average of $26.30 and a 200-day moving average of $27.24. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.44%. The ex-dividend date was Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 121.99%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PFE shares. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.